# Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer

> **NCT01630083** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 252 (actual)

## Conditions studied

- CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
- CLDN18.2-positive Adenocarcinoma of Esophagus
- CLDN18.2-positive Gastric Adenocarcinoma

## Interventions

- **DRUG:** epirubicin
- **DRUG:** oxaliplatin
- **DRUG:** capecitabine
- **DRUG:** zolbetuximab

## Key facts

- **NCT ID:** NCT01630083
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-19
- **Primary completion:** 2019-01-31
- **Final completion:** 2019-01-31
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2025-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01630083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01630083, "Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01630083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*